hTNFR2
모델명
C57BL/6Smoc-Tnfrsf1bem2(hTNFRSF1B)Smoc
카탈로그
NM-HU-190010
모델 상태
Embryo cryopreservation
유전자 요약
Gene Symbol
TNFRSF1B
모델 설명
검증 데이터
Fig.1 Detection of TNFRSF1B expression by RT-PCR.
Wild type: only one band at 247 bp with primers F2/R2(mTnfrsf1b);
Homozygous: only one band at 255 bp with primers F1/R1(hTNFRSF1B);
Abbr.. M, DNA marker; HO, homozygous; HE, heterozygous; WT, wild type.
Fig.2 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in spleen in HE hTNFR2 mice.（In collaboration with CrownBio）
Fig.3 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in Peripheral Blood in HE hTNFR2 mice.（In collaboration with CrownBio）
Fig.4 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in Lymph node in HE hTNFR2 mice.（In collaboration with CrownBio）
Fig.5 Detection of human/mouse TNFRSF1B(TNFR2) expression on T cells in spleen in HO hTNFR2 mice.（In collaboration with CrownBio）
Fig.6 Detection of human/mouse TNFRSF1B(TNFR2) expression on Treg, granulocytes and monocytes in spleen in HO hTNFR2 mice.（In collaboration with CrownBio）
Fig.7 In vivo efficacy evaluation of anti-hTNFR2 in TNFR2 HuGEMM mice with MC38-OVA tumors.（In collaboration with CrownBio）
Homozygous humanized TNFRSF1B mice were inoculated with MC38 colon cancer cells. The drug targeting human TNFRSF1B, showed a very significant anti-tumor effect, demonstrating that the humanized TNFRSF1B mice are a good in vivo model for validating the efficacy of antibodies targeting human TNFRSF1B.
Fig.8 FACS for blood upon TNFR2 antagonist treatment.（In collaboration with CrownBio）
Addition of antagonistic hTNFRSF1B antibody can impair hTNF-induced Treg cells proliferation, while the agonistic hTNFRSF1B antibody alone can induce a modest proliferative response.
Fig.9 TIL analysis upon TNFR2 antagonist treatment.（In collaboration with CrownBio）
1 tumor in hTNFR2 Ab1 treatment group decreased (1/7, TV=0)
2 tumors in hTNFR2 Ab2 treatment group decreased (2/7, TV=0; 3/7 died during dosing period)
Fig.10 TNFRSF1B blockade increases the Teff/Treg ratios in tumor microenvironment. （In collaboration with CrownBio）
당신은 또한 좋아할 수 있습니다
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
조회At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
조회